Compare FCUV & PCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FCUV | PCSA |
|---|---|---|
| Founded | 2012 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9M | 6.1M |
| IPO Year | 2013 | 2012 |
| Metric | FCUV | PCSA |
|---|---|---|
| Price | $3.83 | $2.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | 19.3K | ★ 35.8K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $398,137.00 | $5,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.50 | $0.11 |
| 52 Week High | $12.83 | $8.88 |
| Indicator | FCUV | PCSA |
|---|---|---|
| Relative Strength Index (RSI) | 47.41 | 44.11 |
| Support Level | $3.36 | $1.96 |
| Resistance Level | $4.09 | $2.56 |
| Average True Range (ATR) | 0.60 | 0.31 |
| MACD | -0.16 | -0.06 |
| Stochastic Oscillator | 44.42 | 21.31 |
Focus Universal Inc offers smart devices, IoT products, and patented products and technologies for 5G telecommunications and network security. It is focused on commercializing its universal smart technology and financial reporting software. Its product line includes various digital, analog, and quantum light meters and filtration products, the Ubiquitor universal smart device, SEC Financial Reporting Software, and other smart devices and sensors. The company's reportable segments are Corporate and IoT, which derives maximum revenue, and Perfecular and Lusher. The Corporate and IoT segment includes its LED and IoT installation and management business (under Smart AVX), specializing in LED and display systems, home theaters, lighting control, automation, and integration.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).